Evaluation of the effects of Ellagic acid on inflammation and insulin resistance in patients with Type 2 diabetes mellitus and acute coronary syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220516054874N14

Enrollment

Registered

2024-05-18

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Patients with Type 2 diabetes mellitus and acute coronary syndrome receiving Ellagic acid 200 mg once daily for two months along with standard treatment. Interventi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus Patients with a history of myocardial infarction according to the American College of Heart criteria At least 6 months have passed since the diagnosis of diabetes Age more than 18 years old Consent to admission to the study Patients with fasting serum glucose levels greater than or equal to 125 mg/dl Patients with glycosylated hemoglobin blood levels greater than or equal to 6.5%

Exclusion criteria

Exclusion criteria: Type 1 diabetes Kidney failure and GFR<30 Severe liver failure with liver enzymes three times more than normal Chronic inflammatory disease such as lupus Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Changes in Homeostatic Model Assessment (HOMA-IR). Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.	—

Secondary

Measure	Time frame
Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in CBC diff. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Insulin levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in fasting blood sugar levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Hemoglobin A1c levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Urea levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Creatinine levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in ALT levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in AST levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Interleukin-6 level. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.	—

Measure

Time frame

Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in CBC diff. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Insulin levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in fasting blood sugar levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Hemoglobin A1c levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Urea levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Creatinine levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in ALT levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in AST levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Interleukin-6 level. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Vafa Baradaran Rahimi

Mashhad University of Medical Sciences

baradaranrv@mums.ac.ir0095 5138012739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026